scholarly journals Defective Tumor Necrosis Factor-α-dependent Control of Astrocyte Glutamate Release in a Transgenic Mouse Model of Alzheimer Disease

2005 ◽  
Vol 280 (51) ◽  
pp. 42088-42096 ◽  
Author(s):  
Daniela Rossi ◽  
Liliana Brambilla ◽  
Chiara F. Valori ◽  
Andrea Crugnola ◽  
Giorgio Giaccone ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Alzheimer Disease ◽  
Mouse Model ◽  
Transgenic Mouse ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Glutamate Release ◽  
Transgenic Mouse Model ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals Anti-tumor necrosis factor α treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C

Hepatology ◽  
2010 ◽  
Vol 52 (5) ◽  
pp. 1553-1563 ◽  
Author(s):  
Erwin Daniel Brenndörfer ◽  
Malin Weiland ◽  
Lars Frelin ◽  
Emma Derk ◽  
Gustaf Ahlén ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Tumor Necrosis Factor ◽  
Mouse Model ◽  
Liver Regeneration ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Transgenic Mouse Model ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals Tumor Necrosis Factor-α Antagonist Etanercept Decreases Blood Pressure and Protects the Kidney in a Mouse Model of Systemic Lupus Erythematosus

Hypertension ◽  
2010 ◽  
Vol 56 (4) ◽  
pp. 643-649 ◽  
Author(s):  
Marcia Venegas-Pont ◽  
Michaele B. Manigrasso ◽  
Samira C. Grifoni ◽  
Babbette B. LaMarca ◽  
Christine Maric ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Blood Pressure ◽  
Tumor Necrosis Factor ◽  
Mouse Model ◽  
Lupus Erythematosus ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Systemic Lupus ◽  
Factor Α ◽  
Necrosis Factor

Anti-tumor necrosis factor-α therapy increases plaque burden in a mouse model of experimental atherosclerosis

2018 ◽  
Vol 277 ◽  
pp. 80-89 ◽  
Author(s):  
Raghav Oberoi ◽  
Ann-Kathrin Vlacil ◽  
Jutta Schuett ◽  
Florian Schösser ◽  
Harald Schuett ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Mouse Model ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Experimental Atherosclerosis ◽  
Plaque Burden ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals Inhibition of Inflammation Mediated Through the Tumor Necrosis Factor α Biochemical Pathway Can Lead to Favorable Outcomes in Alzheimer Disease

2017 ◽  
Vol 9 ◽  
pp. 117957351772251 ◽  
Author(s):  
Daniah Shamim ◽  
Michael Laskowski
Keyword(s):  
Tumor Necrosis Factor ◽  
Alzheimer Disease ◽  
Immune Modulation ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Sodium Hydrosulfide ◽  
Tnf Α ◽  
Factor Α ◽  
Necrosis Factor

Tumor necrosis factor α (TNF-α) inhibitors have long been used as disease-modifying agents in immune disorders. Recently, research has shown a role of chronic neuroinflammation in the pathophysiology of neurodegenerative diseases such as Alzheimer disease, and interest has been generated in the use of anti-TNF agents and TNF-modulating agents for prevention and treatment. This article extensively reviewed literature on animal studies testing these agents. The results showed a role for direct and indirect TNF-α inhibition through agents such as thalidomide, 3,6-dithiothalidomide, etanercept, infliximab, exendin-4, sodium hydrosulfide, minocycline, imipramine, and atorvastatin. Studies were performed on mice, rats, and monkeys, with induction of neurodegenerative physiology either through the use of chemical agents or through the use of transgenic animals. Most of these agents showed an improvement in cognitive function as tested with the Morris water maze, and immunohistochemical and histopathological staining studies consistently showed better outcomes with these agents. Brains of treated animals showed significant reduction in pro-inflammatory TNF-α and reduced the burden of neurofibrillary tangles, amyloid precursor protein, and β-amyloid plaques. Also, recruitment of microglial cells in the central nervous system was significantly reduced through these drugs. These studies provide a clearer mechanistic understanding of the role of TNF-α modulation in Alzheimer disease. All studies in this review explored the use of these drugs as prophylactic agents to prevent Alzheimer disease through immune modulation of the TNF inflammatory pathway, and their success highlights the need for further research of these drugs as therapeutic agents.

scholarly journals Tumor Necrosis Factor α and Interleukin 10 Promoter Region Polymorphisms and Risk of Late-Onset Alzheimer Disease

2006 ◽  
Vol 63 (8) ◽  
pp. 1165 ◽  
Author(s):  
Erin M. Ramos ◽  
Ming-Tesh Lin ◽  
Eric B. Larson ◽  
Izumi Maezawa ◽  
Li-Hui Tseng ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Alzheimer Disease ◽  
Promoter Region ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Late Onset ◽  
Interleukin 10 ◽  
Factor Α ◽  
Necrosis Factor

AB0197 Endothelial dysfunction in a mouse model of SLE: A role for tumor necrosis factor-α?:

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 648.15-648
Author(s):  
A. Virdis ◽  
C. Tani ◽  
S. Vagnani ◽  
E. Duranti ◽  
S. Bombardieri ◽  
...  
Keyword(s):  
Endothelial Dysfunction ◽  
Tumor Necrosis Factor ◽  
Mouse Model ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Factor Α ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document